Professor Andrew Pollard
Professor of Paediatric Infection and Immunity
ANDREW J POLLARD, FRCPCH PhD FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Director of the Oxford Vaccine Group, Fellow of St Cross College and Honorary Consultant Paediatrician at the Children’s Hospital, Oxford, UK. He obtained his medical degree at St Bartholomew’s Hospital Medical School, University of London in 1989 and trained in Paediatrics at Birmingham Children’s Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary’s Hospital, London, UK and at British Columbia Children’s Hospital, Vancouver, Canada. He obtained his PhD at St Mary’s Hospital, London, UK in 1999 studying immunity to Neisseria meningitidis in children and proceeded to work on anti-bacterial innate immune responses in children in Canada before returning to his current position at the University of Oxford, UK in 2001. He received the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013 for his contribution to the specialty and the ESPID Distinguished Award for Education & Communication in 2015.
He chaired the UK’s National Institute for Health and Care Excellence (NICE) meningitis guidelines development group, and the NICE topic expert group developing quality standards for management of meningitis and meningococcal septicaemia. He chairs the UK Department of Health’s Joint Committee on Vaccination and Immunisation and the European Medicines Agency scientific advisory group on vaccines and is a member of WHO’s SAGE. His research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He has a particular interest in the development of B cell immunity in early childhood. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal. He also leads a project on burden and transmission of typhoid in Nepal, Bangladesh and Malawi, and trials of typhoid vaccines in South Asia. He has supervised 37 PhD students and his publications include over 500 manuscripts and books on various topics in paediatrics and infectious diseases.
Andrew also leads the clinical trials of Oxford's coronavirus vaccine in the UK, South Africa and Brazil.